Beam Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
540
- Stock Symbol
-
BEAM
- Investments
-
3
- Share Price
-
$20.90
- (As of Friday Closing)
Beam Therapeutics General Information
Description
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Contact Information
Website
www.beamtx.comCorporate Office
- 238 Main Street
- Cambridge, MA 02142
- United States
Corporate Office
- 238 Main Street
- Cambridge, MA 02142
- United States
Beam Therapeutics Timeline
Beam Therapeutics Stock Performance
As of 20-Nov-2026, Beam Therapeutics’s stock price is $20.90. Its current market cap is $2.16B with 103M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $20.90 | $20.94 | $20.39 - $38.26 | $2.16B | 103M | 2.05M | -$1.01 |
Beam Therapeutics Financials Summary
As of 30-Sep-2026, Beam Therapeutics has a trailing 12-month revenue of $147M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,619,814 | 1,889,335 | 1,289,888 | 1,375,671 |
| Revenue | 146,644 | 139,743 | 63,518 | 377,709 |
| EBITDA | (120,769) | (101,431) | (403,872) | (157,825) |
| Net Income | (108,354) | (79,992) | (376,742) | (132,527) |
| Total Assets | 1,269,072 | 1,481,177 | 1,103,824 | 1,459,714 |
| Total Debt | 243,872 | 154,123 | 161,425 | 172,689 |
Beam Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Beam Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Beam Therapeutics Comparisons
Industry
Financing
Details
Beam Therapeutics Competitors (127)
One of Beam Therapeutics’s 127 competitors is Verve Therapeutics, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Verve Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Prime Medicine | Formerly VC-backed | Cambridge, MA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Sharp Therapeutics (Biotechnology) | Formerly VC-backed | Pittsburgh, PA |
Beam Therapeutics Patents
Beam Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026192929-A1 | Methods and compositions for editing an intronic mutation associated with phenylketonuria (pku) | Pending | 10-Mar-2025 | ||
| WO-2026183200-A1 | Targeted lipid nanoparticles | Pending | 26-Feb-2025 | ||
| WO-2026174164-A1 | Nanomaterials comprising triols | Pending | 14-Feb-2025 | ||
| WO-2026169723-A1 | Lipid nanoparticles, methods of making lipid nanoparticles, and uses thereof | Pending | 04-Feb-2025 | ||
| WO-2026161459-A1 | Non-genotoxic conditioning methods and compositions | Pending | 22-Jan-2025 | C07K16/2896 |
Beam Therapeutics Signals
Beam Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Beam Therapeutics Investments & Acquisitions (3)
Beam Therapeutics’s most recent deal was a Merger/Acquisition with Guide Therapeutics for . The deal was made on 23-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Guide Therapeutics | 23-Feb-2021 | Merger/Acquisition | Drug Delivery | ||
| BliNK Therapeutics | 01-Sep-2018 | Merger/Acquisition | Biotechnology | ||
| Verve Therapeutics | 07-Aug-2018 | Early Stage VC | Drug Discovery |
Beam Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
32.65 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Beam Therapeutics Exits (1)
Beam Therapeutics’s most recent exit was on 07-Aug-2018 from Verve Therapeutics. The exit was categorized as with 6 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Verve Therapeutics | 07-Aug-2018 | Completed |
|
Beam Therapeutics FAQs
-
When was Beam Therapeutics founded?
Beam Therapeutics was founded in 2017.
-
Where is Beam Therapeutics headquartered?
Beam Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Beam Therapeutics?
Beam Therapeutics has 540 total employees.
-
What industry is Beam Therapeutics in?
Beam Therapeutics’s primary industry is Drug Discovery.
-
Is Beam Therapeutics a private or public company?
Beam Therapeutics is a Public company.
-
What is Beam Therapeutics’s stock symbol?
The ticker symbol for Beam Therapeutics is BEAM.
-
What is the current stock price of Beam Therapeutics?
As of 20-Nov-2026 the stock price of Beam Therapeutics is $20.90.
-
What is the current market cap of Beam Therapeutics?
The current market capitalization of Beam Therapeutics is $2.16B.
-
What is Beam Therapeutics’s current revenue?
The trailing twelve month revenue for Beam Therapeutics is $147M.
-
Who are Beam Therapeutics’s competitors?
Verve Therapeutics, Prime Medicine, CRISPR Therapeutics, Editas Medicine, and Sharp Therapeutics (Biotechnology) are some of the 127 competitors of Beam Therapeutics.
-
What is Beam Therapeutics’s annual earnings per share (EPS)?
Beam Therapeutics’s EPS for 12 months was -$1.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process